Becotatug vedotin plus pucotenlimab as first-line therapy in patients with recurrent or metastatic nasopharyngeal carcinoma: A phase II clinical trial. This is an ASCO Meeting Abstract from the 2026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results